In particular, by specifically blocking BCR-induced activation of PI3Kδ, we propose that idelalisib activity promotes S1P-mediated egress of CLL cells by relieving BCR-mediated repression of S1PR1 expression. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.